✦ LIBER ✦

Disappearance of the predictive value of prognostic variables in childhood acute lymphoblastic leukemia: A report from childrens cancer study group

✍ Scribed by Harland Sather; Peter Coccia; Mark Nesbit; Carolyn Level; Denman Hammond

Publisher: John Wiley and Sons
Year: 1981
Tongue: English
Weight: 598 KB
Volume: 48
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19810715)48:2<370::aid-cncr2820480224>3.0.co;2-u

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Prognostic factors and therapy in acute

Prognostic factors and therapy in acute lymphoblastic leukemia of childhood: CCG-141: A report from childrens cancer study group

✍ Denis R. Miller; Sandford Leikin; Vincent Albo; Harland Sather; Myron Karon; Den 📂 Article 📅 1983 🏛 John Wiley and Sons 🌐 English ⚖ 811 KB

Prognostic significance of cytogenetic a

Prognostic significance of cytogenetic abnormalities of chromosome arm 12p in childhood acute lymphoblastic leukemia : A report from the Children's Cancer Group

✍ Nyla A. Heerema; Harland N. Sather; Martha G. Sensel; Mei K. Lee; Raymond Hutchi 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB 👁 3 views

## Background: The authors have determined the prognostic significance of cytogenetically detectable 12p abnormalities, which are frequent in children with acute lymphoblastic leukemia (all), in a large cohort of patients treated on risk-adjusted protocols of the children's cancer group (ccg). ##

Birth defects in offspring of adult surv

Birth defects in offspring of adult survivors of childhood acute lymphoblastic leukemia: A Childrens Cancer Group/National Institutes of Health report

✍ Lisa B. Kenney; H. Stacy Nicholson; Cynthia Brasseux; James L. Mills; Leslie L. 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 682 KB

## BACKGROUND. It is not known if therapy for acute lymphoblastic leukemia (ALL) during childhood increases the risk of birth defects in the offspring of adult survivors. The Childrens Cancer Group (CCG), in collaboration with the National Institutes of Health (NIH), conducted a retrospective coho

Phase I/II study of bisantrene in childh

Phase I/II study of bisantrene in childhood cancer: A report from the childrens cancer study group

✍ Movassaghi, Nasser ;Krivit, William A. ;Krailo, Mark D. ;Hammond, G. Denman 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 328 KB

A phase I/II study of bisantrene using a 3-week schedule was undertaken in 171 children with refractory leukemias and solid tumors. The doses ranged from 190 to 430 mg/m2. The maximum tolerated dose for children with solid tumors and acute leukemias was 280 mg/m2 and 360 mg/m2 every 3 weeks, respect

Improvement in CNS protective treatment

Improvement in CNS protective treatment in non-high-risk childhood acute lymphoblastic leukemia: report from the Japanese Children's Cancer and Leukemia Study Group

✍ Tsurusawa, Masahito; Katano, Naoyuki; Yamamoto, Yoshifumi; Hirota, Takahisa; Koi 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 126 KB 👁 3 views

Background. Prevention of central nervous system (CNS) leukemia by early introduction of therapy to this sanctuary site is an essential component of modern treatment strategy for acute lymphoblastic leukemia (ALL). However, the optimal form of preventive CNS therapy remains debatable. Procedure. To

Treatment of overt isolated testicular r

Treatment of overt isolated testicular relapse in children on therapy for acute lymphoblastic leukemia. A report from the childrens cancer group

✍ Jerry Z. Finklestein; Denis R. Miller; James Feusner; Daniel O. Stram; Edward Ba 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 512 KB